The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is a capsule that is taken orally.
55 - 80 years
MCI or a mild form of dementia caused by Alzheimer’s disease
Approximately 1 to 2 years
Amsterdam, Den Bosch or Zwolle